1
|
Savin G, Sastourne-Array O, Caillol S, Bethry A, Assor M, David G, Nottelet B. Evaluation of Porous (Poly(lactide- co-glycolide)- co-(ε-caprolactone)) Polyurethane for Use in Orthopedic Scaffolds. Molecules 2024; 29:766. [PMID: 38398518 PMCID: PMC10891616 DOI: 10.3390/molecules29040766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 02/02/2024] [Accepted: 02/05/2024] [Indexed: 02/25/2024] Open
Abstract
To develop an orthopedic scaffold that could overcome the limitations of implants used in clinics, we designed poly(ester-urethane) foams and compared their properties with those of a commercial gold standard. A degradable poly(ester-urethane) was synthetized by polyaddition between a diisocyanate poly(ε-caprolactone) prepolymer (PCL di-NCO, Mn = 2400 g·mol-1) and poly(lactic-co-glycolic acid) diol (PLGA, Mn = 2200 g·mol-1) acting as a chain extender. The resulting high-molecular-weight poly(ester-urethane) (PEU, Mn = 87,000 g·mol-1) was obtained and thoroughly characterized by NMR, FTIR and SEC-MALS. The porous scaffolds were then processed using the solvent casting (SC)/particle leaching (PL) method with different NaCl crystal concentrations. The morphology, pore size and porosity of the foams were evaluated using SEM, showing interconnected pores with a uniform size of around 150 µm. The mechanical properties of the scaffolds are close to those of the human meniscus (Ey = 0.5~1 MPa). Their degradation under accelerated conditions confirms that incorporating PLGA into the scaffolds greatly accelerates their degradation rate compared to the gold-standard implant. Finally, a cytotoxicity study confirmed the absence of the cytotoxicity of the PEU, with a 90% viability of the L929 cells. These results suggest that degradable porous PLGA/PCL poly(ester-urethane) has potential in the development of meniscal implants.
Collapse
Affiliation(s)
- Gaëlle Savin
- ICGM, Univ Montpellier, CNRS, ENSCM, 34000 Montpellier, France; (G.S.); (G.D.)
- IBMM, Univ Montpellier, CNRS, ENSCM, 34000 Montpellier, France; (O.S.-A.); (A.B.)
- Arthrocart Biotech, 13000 Marseille, France;
| | | | - Sylvain Caillol
- ICGM, Univ Montpellier, CNRS, ENSCM, 34000 Montpellier, France; (G.S.); (G.D.)
| | - Audrey Bethry
- IBMM, Univ Montpellier, CNRS, ENSCM, 34000 Montpellier, France; (O.S.-A.); (A.B.)
| | | | - Ghislain David
- ICGM, Univ Montpellier, CNRS, ENSCM, 34000 Montpellier, France; (G.S.); (G.D.)
| | - Benjamin Nottelet
- IBMM, Univ Montpellier, CNRS, ENSCM, 34000 Montpellier, France; (O.S.-A.); (A.B.)
- Department of Pharmacy, Nîmes University Hospital, University Montpellier, 30900 Nimes, France
| |
Collapse
|